A New Ciprofibrate Calcium Salt with Improved Solubility and Intrinsic Dissolution Rate.

IF 3.7 3区 医学 Q2 CHEMISTRY, MEDICINAL
Bruno Arantes Borges, Kassius de Souza Reis, Camila Batista Pinto, Javier Ellena, Antônio Carlos Doriguetto, Rudy Bonfilio
{"title":"A New Ciprofibrate Calcium Salt with Improved Solubility and Intrinsic Dissolution Rate.","authors":"Bruno Arantes Borges, Kassius de Souza Reis, Camila Batista Pinto, Javier Ellena, Antônio Carlos Doriguetto, Rudy Bonfilio","doi":"10.1016/j.xphs.2024.08.025","DOIUrl":null,"url":null,"abstract":"<p><p>Ciprofibrate (CIP) is an active pharmaceutical ingredient (API) classified as class II on the basis of biopharmaceutical classification system (BCS), what indicates that it has low solubility in aqueous solvents. The use of API salts has attracted attention due to their improvements in solubility, tolerability, higher rate and extent of absorption, and faster onset of the therapeutic effect. In this work, a new crystalline CIP monohydrated calcium salt (Ca(CIP)<sub>2</sub>.H<sub>2</sub>O) was successfully obtained and its crystal structure determined by single crystal X-ray diffraction analysis (SCXRD). Additionally, Ca(CIP)<sub>2</sub>.H<sub>2</sub>O was widely characterized by powder X-ray diffraction (PXRD), Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and submitted to solubility, intrinsic dissolution and accelerated stability studies. Ca(CIP)<sub>2</sub>.H<sub>2</sub>O exhibited higher solubility and dissolution rate than CIP-free form and was stable up to 6 months at 40 °C (75 %RH). Therefore, Ca(CIP)<sub>2</sub>.H<sub>2</sub>O may be a viable alternative for use in solid dosage forms.</p>","PeriodicalId":16741,"journal":{"name":"Journal of pharmaceutical sciences","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmaceutical sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.xphs.2024.08.025","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Ciprofibrate (CIP) is an active pharmaceutical ingredient (API) classified as class II on the basis of biopharmaceutical classification system (BCS), what indicates that it has low solubility in aqueous solvents. The use of API salts has attracted attention due to their improvements in solubility, tolerability, higher rate and extent of absorption, and faster onset of the therapeutic effect. In this work, a new crystalline CIP monohydrated calcium salt (Ca(CIP)2.H2O) was successfully obtained and its crystal structure determined by single crystal X-ray diffraction analysis (SCXRD). Additionally, Ca(CIP)2.H2O was widely characterized by powder X-ray diffraction (PXRD), Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and submitted to solubility, intrinsic dissolution and accelerated stability studies. Ca(CIP)2.H2O exhibited higher solubility and dissolution rate than CIP-free form and was stable up to 6 months at 40 °C (75 %RH). Therefore, Ca(CIP)2.H2O may be a viable alternative for use in solid dosage forms.

一种新的环丙贝特钙盐,其溶解度和内在溶解速率均有所提高。
环丙贝特(CIP)是一种活性药物成分(API),根据生物制药分类系统(BCS)被归为第二类,这表明它在水性溶剂中的溶解度较低。由于原料药盐具有更好的溶解性、耐受性、更高的吸收率和吸收范围以及更快的治疗效果,其使用已引起人们的关注。在这项研究中,我们成功获得了一种新型结晶的 CIP 一水钙盐 (Ca(CIP)2.H2O),并通过单晶 X 射线衍射分析 (SCXRD) 确定了其晶体结构。此外,还通过粉末 X 射线衍射 (PXRD)、傅立叶变换红外光谱 (FTIR)、差示扫描量热法 (DSC)、热重分析 (TGA) 对 Ca(CIP)2.H2O 进行了广泛表征,并对其进行了溶解度、内在溶解度和加速稳定性研究。与不含 CIP 的形式相比,Ca(CIP)2.H2O 表现出更高的溶解度和溶解速率,并且在 40°C (75%RH)条件下可稳定长达 6 个月。因此,Ca(CIP)2.H2O 可以作为固体制剂的一种可行替代品。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.30
自引率
13.20%
发文量
367
审稿时长
33 days
期刊介绍: The Journal of Pharmaceutical Sciences will publish original research papers, original research notes, invited topical reviews (including Minireviews), and editorial commentary and news. The area of focus shall be concepts in basic pharmaceutical science and such topics as chemical processing of pharmaceuticals, including crystallization, lyophilization, chemical stability of drugs, pharmacokinetics, biopharmaceutics, pharmacodynamics, pro-drug developments, metabolic disposition of bioactive agents, dosage form design, protein-peptide chemistry and biotechnology specifically as these relate to pharmaceutical technology, and targeted drug delivery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信